Ionis reports first quarter 2021 financial results and recent business achievements
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends up on Iran war peace deal hopes, SpaceX's historic debut
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Ionis Pharmaceuticals (IONS) Misses Q1 EPS by 11c, Revenues Miss
May 5, 2021 7:17 AM EDTIonis Pharmaceuticals (NASDAQ: IONS) reported Q1 EPS of ($0.64), $0.11 worse than the analyst estimate of ($0.53). Revenue for the quarter came in at $112 million versus the consensus estimate of $128.7 million.
"In the first quarter, we took important steps to maximize the value of our wholly owned... More
